Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
Anwen Xiong(Tongji University), Caicun Zhou(Tongji University)
Cited by 38
Related Papers
Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma
|Journal of Hematology & Oncology|2019|107
Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment
|Experimental Hematology and Oncology|2024|29
CD39: the potential target in small cell lung cancer
|Translational Lung Cancer Research|2020|22
Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer
|Journal for ImmunoTherapy of Cancer|2022|12